Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC
Status:
Withdrawn
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of P nab-paclitaxel combined with carboplatin versus
paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide in the
neoadjuvant treatment of triple negative breast cancer.